Skip to main content

29-01-2019 | Rheumatology | News | Article

News in brief

IBD ‘uncommon’ in patients treated with secukinumab

medwireNews: Inflammatory bowel disease (IBD) is an “uncommon” occurrence among patients with psoriatic arthritis (PsA), ankylosing spondylitis (AS), or psoriasis who are treated with the interleukin (IL)-17A inhibitor secukinumab, researchers report.

The pooled analysis included a total of 7355 patients from 21 clinical trials with a cumulative secukinumab exposure of 16,2260.9 patient–years. In all, three of 1380 patients with PsA developed ulcerative colitis, three developed Crohn’s disease, and unclassified IBD was reported in two patients, giving exposure-adjusted incidence rates (IRs) of 0.08, 0.08, and 0.05 per 100 patient–years, respectively.

Similarly, the corresponding exposure-adjusted IRs were 0.2, 0.4, and 0.1 per 100 patient–years for the 794 patients with AS, and 0.13, 0.05, and 0.01 per 100 person–years for the 5181 patients with psoriasis.

These rates “appear to be within the range of expected background IRs” for patients with PsA, AS, and psoriasis, and “did not increase over time,” write Stefan Schreiber (Christian-Alrechts-University, Kiel, Germany) and fellow researchers in the Annals of the Rheumatic Diseases.

They note, however, that given previous reports of IBD exacerbations in patients treated with secukinumab, “[c]aution is recommended when prescribing IL-17 inhibitors to patients with active IBD in the special warnings section of the summary of product characteristics for secukinumab and these patients should be followed closely.”

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

See also:

See the research in context now

with trial summaries, expert opinion and congress coverage